

## CURRICULUM VITAE

### Judith D. Bentkover, Ph.D.

807 Boston Neck Road

Narragansett, RI 02882

Mobile: 617.953.1664

Email: judithbentkover@gmail.com

## EDUCATION

1978	Economics	Ph.D. Omicron Delta Epsilon	Tufts University (dissertation and health economics studies at Harvard University) Dissertation: "An Empirical investigation of the Impact of Inflation and Unemployment on Public vis-à-vis Private Community Hospital Utilization."
1971	Economics	M.A. Omicron Delta Epsilon	Tufts University
1970	Economics	B.A. <i>cum laude</i> & honors in economics	Douglass College, Rutgers University

## POSTDOCTORAL TRAINING AND FELLOWSHIPS

1984- 1987	Health Policy Research and Education	Harvard University (HSPH, KSG, GSAS, HMS)	Christopher J. Walker / Richard King Mellon Research Fellowships Directed and participated in the development of a joint Harvard-American Medical Association research project concerning the influence of multi-hospital systems on physician behavior; served as co-executive officer of the Working Group on Innovations in the Organization and Financing of Health Care, and coordinator of a health policy seminar; member of the Harvard Medicare Project.
---------------	--	---	---

1974	Kaiser Family Foundation	Group Health Cooperative, Seattle	Investigator Fellowship An evaluation of surgical assistants versus surgeons assisting other surgeons in a prepaid group practice setting.
------	--------------------------	-----------------------------------	---

**ACADEMIC APPOINTMENTS**

2014- 2017	Executive Director	Exec Master of Healthcare Leadership (EMHL)	Brown University
2011- 2017	Academic Director & Member of Leadership Team	Exec Master of Healthcare Leadership	Brown University
2015- Present	Professor of the Practice	Health Services, Policy, and Practice School of Public Health	Brown University
2011- Present	Professor of the Practice	Department of Economics	Tufts University
2010- 2015	Adjunct Professor of Community Health	Alpert Medical School	Brown University
1990 – Present	Outside Thesis Advisor As asked	Heller School	Brandeis University
1989- 1991	Director, Health Policy Ph.D. Program	Division of Health Policy Research and Education	Harvard University HSPH, KSG, HMS, GSAS
1989- 1990	Lecturer	Continuing Professional Education	Harvard University
1987- 1988	Director, Applied Research Programs	Health Policy and Management	Harvard School of Public Health/ Kennedy School of Government
1987- 1990	Special Instructor	Health Care Administration	Simmons College (Graduate Division)
1986- 1990	Adjunct Lecturer In Public Policy	Kennedy School of Government	Harvard University

1985-1990	Lecturer in Economics	Health Policy and Management	Harvard School of Public Health
1984-1985	Visiting Lecturer	Health Policy and Management	Harvard School of Public Health
1981	Lecturer	Department of Community Health	Tufts Medical School
1978-1980	Instructor	Department of Economics	Simmons College
1976-1978	Visiting Lecturer In Economics	Department of Economics	Boston State College
1976	Teaching Fellow	Economics	Tufts University

### **GUEST LECTURES**

Health Policy and Program Evaluation, Cost-Effectiveness Analysis, Therapy Economics, Pharmacoeconomics

Audience was primarily life sciences industry associations, academic meetings (ISPOR), Disease-specific and medical associations (global, US) 1980-2010

### **OTHER**

Identified in The Health Care 500 as one of the most influential health care policy makers in the United States (1990s)

RI Healthcare Reform Commission (from inception through present time)

Collie Rescue League (1991 – present)

### **BOARD OF DIRECTORS**

Health Imperatives: Finance Committee 2010 - 2016

Water Fire: Governance Committee Chair 2010 - Present

Arthur D. Little Alumni Association 1995 – 2000

Rhode Island Health and Education Building Corporation 2016 - Present

### **TEACHING EXPERIENCE (EXEC EDUCATION AND ACADEMIC)**

*International – Contracted by International Executive Education companies, investment groups, and various pharmaceutical/medical device organizations*

1990 – 2005 – Conference speaker at 2-3 life sciences and medical association conferences per year throughout U.S.(NY, Chicago, San Francisco, LA, Atlanta, Houston) , Europe (France, Germany, UK, Italy, Sweden, Denmark, Netherlands, Belgium), Asia (Tokyo, Singapore) on US Health Care Market and Trends, US Healthcare System, Global Trends and Outlook for the Global Pharmaceutical Industry, The Strategic Application of Pharmacoeconomics in Global Product Pricing, Parallel Trade in Life Sciences and its Implication on Global Revenues, several Cost of Illness Talks (urinary incontinence, irritable Bowel Syndrome, depression, cancer, cardiovascular disease)

1998-2005 – Lecturer, Exec Ed, IIR/IPT International Exec Ed/Conference Company; taught intensive courses to high level pharma, biotec, medical device executives and government officials in major European cities on the following topics: strategic use of health economics, product reimbursement, product pricing, parallel trade, pharmacoeconomics, therapy economics, outcomes, and evidence-based medicine, NICE compliance. In addition, several international corporations invited me to teach tailored versions of these courses to their execs and top management (Baxter, Roche, Novartis, SmithKline Beecham, Pharmacia, Boehringer Ingleheim, Yamanouchi, Sanofi, Pfizer, Aventis Behring, Aventis).

*Academic Teaching, Grant Writing, other Academic Responsibilities*

2010-Present –Brown School of Public Health). Developed and taught courses:

- Therapy Econ
- Race to Inner Space (co-taught with John Donoghue, Patrick Kennedy)
- Independent Studies including Theses
- Applied Research Supervision
- Healthcare Policy (EMHL)
- Data-driven Decisionmaking (EMHL)
- Critical Challenge Project (EMHL)

*Other academic responsibilities.*

- Developed curriculum for EMHL.
- Identified teaching faculty, advisors, guest lecturers for EMHL.
- Served on Dept. Committees:

- Strat Planning,
- PhD Admissions.
- Supported 2 research projects (Self-report, PHARMOS),
- Participated in Alzheimer's research grants, One Mind research grant (wrote proposal and served as PI),
- Advised undergrad, MPH, and PhD students.
- Wrote recommendations.
- Participated in graduate student activities related to faculty lunches, job counseling.

2012 – Present – Professor of the Practice, Tufts Econ Dept. Developed and taught

- Health Econ course each semester in Health Econ for undergraduates.

*Other academic responsibilities.* Wrote recommendations, met with students re job counseling. Course voted by students as being in the Top 3 most useful courses.

1989-1991 – Director, Ph.D. Health Policy Program, Harvard University, Cambridge, Massachusetts. Managed the combined doctoral program of Harvard Medical School, Harvard School of Public Health, and Kennedy School of Government; point of contact with students and Executive Committee, monitored budgets, organized health policy seminars; sat on Admissions Committee; fund raising activities; proposal preparation; budget preparation and monitoring; annual report preparation for the relevant Deans; progress reports to outside funding agencies; student-faculty interaction.

- Taught applied research seminar at KSG for health policy students

1987-1988 – Director and Lead Instructor, Applied Research Program in Health Policy and Management, Harvard School of Public Health; located, developed, and supervised internships; instructor of class sessions.

1987 - 1990 – Special Instructor, Simmons College; instructor of required course in health economics (graduate program in Health Care Administration and policy-oriented electives).

1986 - 1990 – Adjunct Lecturer in Public Policy, Harvard University, Kennedy School of Government; developed and taught elective courses offered in health care policy; guest lecturer in program evaluation and applied research courses. Faculty Member of the Senior Common Room of Quincy House, Harvard University. Wrote proposal to undertake research on Migrant Workers (Millbank Foundation) with John Dunlop. Wrote proposal to fund intercollegiate (HSPH, KSG, GSAS, HMS) doctoral program (Sloan Foundation) with John Dunlop. Taught in Harvard's Continuing Professional Education a course entitled The Economics of HIV and AIDS. Taught Access to Health Care for the Uninsured.

1985 - 1990 – Lecturer in Economics, Department of Health Policy and Management, Harvard

School of Public Health; lecturer and course development; preparation of grant proposals; development and implementation of research on technology assessment. Wrote grant proposal to start and continue the research center “Technology Assessment Group” (with Fred Mosteller). Taught Research Methods, Econometrics.

1984 - 1985 – Visiting Lecturer of Health Policy and Management, Harvard School of Public Health; instructor of advanced course in health economics. Faculty advisor of Journal Club. Taught required courses as needed (e.g. Quantitative Methods) during sabbatical or other absences of other faculty members. Served on committees to develop and teach required and elective courses. Taught Economics of Health Care Policy.

1981 – Lecturer, Department of Community Health, Tufts Medical School; instructor in a short elective course offered to medical students.

1978 - 1980 – Instructor in Economics, Simmons College; taught microeconomics and principles of macro and micro.

1976 - 1978 – Visiting Lecturer in Economics, Boston State College; instructor; taught principles of macro and microeconomics.

## **OTHER PROFESSIONAL EXPERIENCE:**

2018- Present	President	Judith Bentkover & Associates
	Educational Program strategic planning and development for on-campus/on-line certificate and degree programs	
	Biopharmaceutical and medical device product and service reimbursement, sales, and pricing	
	Healthcare provider, payer, manufacturer strategic planning	

1998 -  
2013

President & CEO

Innovative Health  
Solutions Corp.

Advised board and top management on critical strategic decisions regarding new lines of business, product prioritization, marketed to target customers, reimbursement, and growth in Fortune 100 and start-up companies.

Provides services and products based on the application of economic, financial, and cost-effectiveness analysis into marketing and sales tools resulting for improved performance of health care products. Enables clients to respond quickly, efficiently, and effectively to the complex and evolving forces within the healthcare marketplace. Clients include Aventis, Bayer, Merck, Novartis, Organon, Pfizer, Pharmacia, Schering-Plough, Shire, Wyeth, Baxter, The Medicines Company, Medtronic, Abbott, Hospira, and Thoratec. Markets include: Asia, Europe, North America, and South America.

- Delivered market forecasting, trend analyses, competitor evaluation, technology assessment, and business planning ensuring that planning and funding decisions were made successfully.
- Strategically analyzed and explained the forces facing biomedical firms and shaping the markets for their products; developed reimbursement plans; demonstrated product value through pharmacoeconomic and cost-effectiveness outcomes and quality of life studies and communicated the economic value of new technologies appropriately to each payer.
- Designed and implemented pricing studies, strategic planning, market research, focus groups, creative supplier-provider collaborations, Phase IV studies so that manufacturers understood customers and were able to tailor products and services to specifically meet customer needs and customers realized the full value of new products and services.

- Designed and implemented medical outcomes, pharmacoeconomic, cost-of-illness/injury studies associated with various medical conditions and alternative treatments.
- Analyzed determinants of compliance and persistence with various medical treatment regimens.
- Examined attributes and concerns of caregivers of patients.
- Investigated needs of patients and concerns of physicians.

1995-1998	Partner-in-Charge	KPMG
	<p>Global practice leader for Strategic Health Solutions, a consulting group serving pharma, biotech, and medical device companies to help them undertake research necessary to get their products approved, priced, sold, and reimbursed globally. Worked for most global pharma and medical device companies and several small – midsize biopharma companies. Grew budget from \$60 million to \$90 million and supervised worldwide group.</p>	
1993	President & CEO	Judith D. Bentkover & Associates
	<p>Started a virtual consulting company serving pharma, biotech, and medical device companies to help them undertake research necessary to get their products approved, priced, sold, and reimbursed globally. Company was purchased by KPMG within the founding year.</p>	
1990-1993	Vice-President	Arthur D. Little, International
	<p>Developed and supervised international projects involving health economics and policy, trains global junior staff and participates in corporate decision-making regarding long-and short-term international operations. Responsible for bringing in \$2 – 6 million business per year.</p>	



1988-1990	<p>Staff to John Dunlop</p> <p>Worked with John Dunlop to devise viable health care policy compromises re health care cost containment, access to health care for the uninsured, scope of covered benefits, topical health care issues.</p>	<p>Dunlop Group of 6: AFL-CIO, AHA, AMA, HIAA, Blue Cross/Blue Shield, Business Roundtable</p>
1987-1990	<p>Senior Economist</p> <p>Developed proposals; served as principal investigator; supervised health policy researchers; planned and directed Scientific Seminar Series; and assumed some management responsibilities related to the Harvard Health Services Research Unit.</p> <p>Worked with Harvard colleagues studying low back pain and the likelihood of receiving one of alternative treatments.</p>	<p>Veterans Administration Health Services Research and Development</p>
1985-1987	<p>Consultant</p> <p>Worked with AFL-CIO and other sponsors of a single payor system to draft a prototype national health insurance plan.</p>	<p>Committee for National Health Insurance</p>
1985-1990	<p>Technical Review Board Member</p> <p>Advised Board re decisions relating to the use of data on MA hospitals' utilization and costs.</p>	<p>Massachusetts Health Data Consortium</p>
1985-1990	<p>Freelance Consultant</p> <p>Evaluated the rate and reserve adequacy for the CA Health Facilities Construction Loan Insurance Fund (State of CA), estimated economic costs and benefits of alternative nutrition management therapies for a major medical projects corp., prepared legal testimony pertaining to health care capital expenditure program appeals for hospitals and law firms, expert witness re cost of illness/cost of injury for major law firms litigating cases re to alleged vaccine-related events.</p>	<p>Clients include Arthur D. Little, Inc., SysteMetrics, law firms; local state, and federal government agencies</p>
1978-1984	<p>Director of Policy Analysis and Special Projects</p> <p>Supervised and participated in community health care cost containment project development</p>	<p>Greater Boston Forum for Health Action</p>

activities pursuant to a planning grant funded by Robert Wood Johnson under the Community Programs for Affordable Health Care; wrote testimony on barriers to access to health care services in the Greater Boston area; and was responsible for all foundation grant fund-raising efforts. Established a research program involving the Forum's members from Boston-area universities, industry, providers, payers and patient advocacy groups.

1984-1985      Manager, Health Economics and Policy Unit      Arthur D. Little, Inc.

Responsible for supervision of professional and support staff who develop and implement projects involving demonstrations, evaluations, health industry environmental assessment, strategic planning and economic impact analysis; and conducted extensive research and analysis on projects concerned with both public and private sector health care cost analysis and program evaluation, including:

- A major project involving the evaluation of competitive incentives in health benefits programs (DHHS)
- A special study of hospitals in fiscal distress (DHHS)
- A review of cost containment activities (for NH/VT Blue Cross/Blue Shield)
- An evaluation of actions that industry could implement in order to contain rising health care costs (for Financial Executives Research Foundation)

1974-1978      Senior Economist      Policy Analysis, Inc.

Responsible for organizing, supervising and conducting government research in the field of health economics. Projects included development contract of a prospective hospital reimbursement plan in MA; study of the effect of adverse economic conditions on the access of the poor to ambulatory health care; development of socioeconomic models of families and/or

households with alcohol-related problems; and the evaluation of cost revenue and control group data as part of an analysis of prospective payment systems for upstate New York.

1971-1973 Foreign Economic Analyst Exxon Corporation

Responsibilities included an analysis of developments and trends in international finance for the purpose of assessing overall investment environment, preparation of recommendations of issues of international monetary policy, balance of payments, international capital markets and evaluation of currency movements.

## **OTHER PROFESSIONAL SERVICE**

National Academy of Sciences Panel to study single shell tanks at Hanford, Washington 1987-1990

American Diabetes Association Fund raiser and lecturer re the costs of diabetes 1997-1998

## **REVIEWER FOR PROFESSIONAL JOURNALS**

- The American Journal of Public Health
- Public Health Briefs
- Medical Care
- Health Care Financing Review
- Inquiry
- Health Affairs
- NEJM
- JAMA
- Value in Health
- Clinical Therapeutics
- Various medical specialty journals (e.g., Cardiology, Urology)

## **PROFESSIONAL SOCIETIES AND BOARDS (and approximate years of membership)**

Rhode Island Health and Educational Building Corp. 2017 - present

Health Imperatives Board of Directors 2010 - 2016

American Economics Association 1978 - 1993

American Public Health Association 1978 - 1993

Arthur D. Little Alum Association Board of Directors 1993 - 2000

Association for Health Services Research 1978 - 1993  
The Boston Club (Women Leaders in the Boston Area) 1990 - 2013  
Health Economics Research Organization 1978 - 1993  
New England Women Economics 1978 - 1993  
International Society for Pharmaceutical Outcomes Research 1995 - 2010  
Medical Outcomes Trust  
Monitor Advisory Board 1995 - ongoing  
Association for Pharmacoeconomics and Outcomes Research 1990 - 1995  
Drug Information Association 1990's  
Health Economics Research Organization 1980's  
Academy Health (late 1990's through 2012)

### **MAJOR RESEARCH INTERESTS:**

Pharmacoeconomics (Therapy Economics), Evidence-based medicine, Outcomes research  
Technology Assessment  
Health Policy Evaluation and Analysis, especially related to Financing and Delivery of Services, Access to Services  
Health Policy & Program Development and Implementation  
Data Driven Decisionmaking  
Mental Health Policy  
Pharmaceutical Product Adherence, Compliance  
Policies and Financing related to Alzheimer's Disease and Related Disorders

### **PUBLICATIONS**

#### *Articles and Reports*

##### *Peer-reviewed*

- Dumbaugh K, Bentkover J, Neuhauser D. Public hospitals: an evaluation. In: Health services: the local perspective. Montpelier, Vermont: Levin A, ed. Capital City Press, Proceedings of the Academy of Political Science, 1977; 32(3): 148-158. *Peer-reviewed.*
- Lewit EM, Bentkover JD, Bentkover SH, Watkins RN, Hughes EF. A comparison of surgical assisting in a prepaid group practice and a community hospital. *Med Care* 1980; 18(9): 916-929. *Peer-reviewed.*
- Bentkover J, Drew P. Cost benefit/cost effectiveness of medical technologies: a case study of orthopedic joint implants. In: The implications of cost-effectiveness analysis of medical technology, Washington, D.C.: U.S. Government Printing

- Office, 1981. *Reviewed by Office of Technology Assessment and OTA-chosen academic reviewers.*
- Bentkover JD, Feeley FG, Hancock R, Johnston J, Lawrence D, Tilson H. An evaluation of a model health plan for the medically needy in Multnomah County, Oregon. *Public Health Rep* 1982; 97(3): 244-50. *Peer reviewed.*
  - Bentkover J, Lee AJ, Vakalis N. Medical manpower for Ontario. Toronto, Canada: The Ontario Council of Health, 1983. *Report reviewed by Ontario Government reviewers, including academics.*
  - Bentkover J. Drew P. Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; (OTA-BP-H-9(14)) *Grant-funded by Office of Technology Assessment (OTA); reviewed by reviewers chosen by OTA.*
  - Bentkover JD. Choice, costs and competition. *Bests Rev Life Health Insur Ed* 1984; 84(9): 12-24. *Peer reviewed.*
  - Bentkover JD, Schroeder RE, Lee AJ. Effects of rate review on the financial viability of New York hospitals: a retrospective assessment. *Hospital and Health Service Administration* 1985; 30(3): 94-105. *Peer-reviewed.*
  - Schlesinger M, Bentkover J, Blumenthal D, Custer W, Musacchio R, Willer J. The privatization of health care and physicians' perceptions of access to hospital services: profits, competition and multi-hospital corporations. *The Milbank Quarterly*. 1987; 65(1): 25-58. *Peer-reviewed.*
  - Bentkover J. CBA/CEA of pharmaceuticals: methods and applications. *Drug Information Journal*. 1988; 22:291-309. *Peer-reviewed.*
  - Bentkover JD. Reducing high blood cholesterol levels with drugs. *JAMA* 1991; 265(15). *Peer-reviewed.*
  - Bentkover JD, Sheshinski RH, Hedley-Whyte JH, Warfield CA, Mosteller F. Low back pain: Laminectomies, spinal fusions, demographics and socioeconomics. *International Journal of Technology Assessment on Health Care (England)* 1992; 8(2): 309-317. *Peer-reviewed.*
  - Getz KA, Bentkover JD. The impact of AIDS on the insurance industry. *Journal of the American Society of CLU & CHFC* 1992; 54-60. *Peer-reviewed.*
  - Bentkover JD, Champion A. Economic evaluation of alternative methods of treatment for diabetic foot ulcer patients: Cost-effectiveness of platelet releasate and wound care clinics. *Wounds* 1993; 5(4):207-215. *Peer-reviewed.*

- Bentkover JD, Baker AM. Health care policy reform: implications for the pharmaceutical industry. *Journal of Research in Pharmaceutical Economics* 1994; 5(3): 17-35. *Peer-reviewed.*
- Bentkover JD, Baker AM, Kaplan H. Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol. *Pharmacoeconomics* 1994; 5(4):335-342. *Peer-reviewed.*
- Bentkover JD, Feighner JP. Cost Analysis of paroxetine versus imipramine in major depression. *Pharmacoeconomics (New Zealand)* 1995; 8(3): 223-232. *Peer-reviewed.*
- Lapierre Y, Bentkover JD, Schainbaum S, Manners S. Direct cost of depression: analysis of treatment costs of paroxetine versus imipramine in Canada. *The Canadian Journal of Psychiatry* 1995; 40(7): 370-377. *Peer-reviewed.*
- Bentkover JD, Field C, Greene EM, Plourde V, Casciano J. The economic burden of irritable bowel syndrome in Canada. *Canadian Journal of Gastroenterology (Canada)* 1999; 13(Suppl. A): 89A-96A. *Peer-reviewed.*
- Langman M, Kahler KH, Kong SX, Zhang Q, Finch E, Bentkover JD, Stewart EJ. Drug switching patterns among patients taking nonsteroidal anti-inflammatory drugs: A retrospective cohort study of a general practitioners database in the United Kingdom. *Pharmacoepidemiology and Drug Safety* 2001; 10:1-8. *Peer-reviewed.*
- Vohr BR, Oh W, Stewart EJ, Bentkover JD, Gabbard SA, Lemons J, Papile LA, Pye R. A comparison of costs and referral rates of three universal newborn hearing screen protocols. *Journal of Pediatrics* 2001; 139(2): 238-244. *Peer-reviewed.*
- Bentkover J, Bachleda M, Kulseng-Hansen S, Corey R, Kurth H. An economic model of overactive bladder in Norway. *Value in Health* 2002; 5(3): 289-294. *Peer-reviewed.*
- Bentkover JD, Corey R. Effective utilization of pharmacoeconomics for decision makers. *Dis Manage Health Outcomes* 2002; 10(2) 75-80. *Peer-reviewed.*
- Coyne K, Revicki T, Hunt T, Corey R, Stewart W, Bentkover J, Kurth H, Abrams P. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. *Quality of Life Research* 2002; 11:563-574. *Peer-reviewed.*
- Kurth H, Pieters R, Bentkover J, Bhattacharyya S, Dhawan R, Sloesen B. An economic model of unstable bladder in Belgium. *Value in Health* 2002; 5(6). *Peer-reviewed.*

- Lemons J, Fanaroff A, Steward EJ, Bentkover JD, Murray G, Diefendorf A. Newborn Hearing Screening: Costs of Establishing a Program. *Journal of Perinatology* 2002; 22:120-124. *Peer-reviewed.*
- Wagner TH, Hu T-W, Bentkover J et al. Health-related consequences of overactive bladder. *Am J Mgd Care* 2002 Dec;8 (19 Suppl): S598-607. *Peer-reviewed.*
- Martinez-Murillo C, Quintana S, Ambriz R, Benitez H, Berges A, Collazo J, Esparza A, Pompa T, Taboada C, Zavala S, Larochele MR, Bentkover JD, on behalf of the Comité Mexicano de Hemostasia y Trombosis (CMHT) Economic Model of Haemophilia in Mexico Research Team. An economic model of haemophilia in Mexico. *Haemophilia* 2004; 10:9-17. *Peer-reviewed.*
- Bloom MA, Barghout V, Kahler KH, Bentkover J, Kurth H, Gralnek IM, Spiegel BMR. Budget impact of tegaserod on a managed care organization formulary. *Am J Manag Care* 2005; 11:S27-S34. *Peer-reviewed.*
- Gaugris S, Heaney RP, Boonen S, Kurth H, Bentkover JD, Sen SS. Vitamin D inadequacy among post-menopausal women: a systematic review. *QJM* 2005; 98(9):667-676. *Peer-reviewed.*
- Bentkover, J, Dorian, P., Thibault, B., Gardner, M (2007), Economic Analysis of a Randomized Trial of Biventricular Pacing in Canada. *Pacing and Clinical Electrophysiology*, 30(1): 38-43. *Peer-reviewed.*
- Bentkover J, Cai,S, Makineni R, Mucha L, Treglia M, Mor V. Road to the Nursing Home: Costs and Disease Progression Among Medicare Beneficiaries with ADRD. *AmJ Alzheimers Dis Other Demen* 2012: 27: 90-99. *Peer-reviewed.*
- Martinez, C, Raparla, S, Plauschinat, C, Giardino, N, Rogers, B. Beresford, Bentkover, J, Schachtner-Appel,A, Curtis,J, Martinez, F, Han, M. Gender Differences in Symptoms and Care Delivery for Chronic Obstructive Pulmonary Disease. *Journal of Women's Health* 2012: 21:1267-1274. *Peer-reviewed.*
- Bentkover, J, Aldern, C, Lerner, D, Richardson, E, Chadha, A, Jacques, C, Bautista-Saeyan, S. Consumer Information and Treatment Resources for Posttraumatic Stress Disorder: Within Reach but Not Grasp. *Harvard Review of Psychiatry* 2015: 23:426-437. *Peer-reviewed.*

#### ***Trade Press and General Press***

- Bentkover J, Venable A, Wolfe H. Implications of Health Care Cost Containment for U.S. Employers and the Health Care Industry. *Impact. Boardroom Reports.* 1979:1-12. *Trade press.*
- Bentkover J, Hughes R. U.S. Health Care Trends Through 1990. *Impact.* 1980:1-

16. *Report issued by Decision Resources and reviewed in accordance with their process.*
- Bentkover J. Reagan Economics: Implications for Health Care. Synapse. 1981:3. *Published by Decision Resources and reviewed in accordance with their process.*
  - Bentkover J, Feeley F. Is Competition the Cure for Rising Health Care Costs? Synapse. 1982:4. *Report printed and issued by Arthur D. Little.*
  - Bentkover J. New ways to hold down the soaring cost of health benefits. Regardless of the Company's Size. Boardroom Reports, 1984:13(3):5-6. *Trade Press.*
  - Bentkover J with Mundel D. Health Cost Still Puzzles. Boston Business Journal. 1984.
  - Bentkover JD. Health economics – Current practices in Europe and the US. Talking Points. Scrip 1993. *Trade press – reviewed.*
  - Stason WB, Bentkover JD. Insights from the VA quality management system project. VA Practitioner 1989; 6(11):35-44. *Trade press.*
  - Bentkover JD, Baker AM. Achieving a competitive edge in the more-challenging U.S. health care regulatory and delivery environment. Spectrum 1991; 22:1-9. *Trade press.*
  - Bentkover JD, Minnear M. Is managed care friend or foe? Scrip Magazine 1996. *Trade press.*
  - KPMG. Biopharmaceutical Industry Key Issues Survey 1996. *KPMG.*
  - KPMG. Integrated Patient Care: Managing Health Care Costs, Maximizing Health Care Value and Quality 1996. *KPMG.*
  - Bentkover JD, Baker AM. Prosperous changes: New pricing plans spell success. Pharmaceutical Executive 1992 Nov. *Trade press.*
  - Bentkover JD, Lash C. Health care reform under the Clinton administration: A Stakeholder's Guide. Spectrum 1993 Mar; 44-1-44-13. *Trade press.*
  - Bentkover J. Mental-health parity can cut costs. Providence Journal 2012: December 21. *General press.*
  - Kennedy PJ, Bentkover J. Veterans returning with terrible burden. Providence Journal 2011: December 5. *General press.*



- Bentkover J. Leadership is Central to Healthcare System Reform. Becker's Hospital Review 2012. *Trade press.*

### ***Books and Chapters***

- Austin, J, Bentkover, J, Chait, L. Leading Strategic Change in an Era of Healthcare Transformation. Springer, 2016.
- Sloan F, Bentkover J. Access to Ambulatory Care and the U.S. Economy. Lexington, MA: D.C. Health & Company, 1979. *Reviewed by several health economists prior to publication as an academic book.*
- Wolfe H, Bentkover J, Schaufler H, Venable A. Health care cost containment: challenge to industry. New York: Financial Executives Research Foundation, 1980. *Reviewed by a group of CFOs of Fortune Top 25 Companies.*
- Vinger P, Bentkover J, Sullivan R, Kalin J. The ice hockey face guard: health care costs and ethics. In: Castaldi C, Hoerner E, Eds. Safety in ice hockey. American Society for Testing and Materials, 1989:58-62. *Invited chapter.*
- Tolpin H, Bentkover J. Economic cost of illness: decision making applications and practical considerations. In: Scheffler R, Rossiter L, eds. Advances, in health economics and health service research, Vol. 4, pp. 165-198, 1983. *Reviewers chosen by book editors.*
- Bentkover J, Venable A. Case Study: Teamsters Central States Health and Welfare Fund, Houston, TX. In: Boland P, ed. A Guide to PPOs Dow Jones-Irwin for Purchasers, Payors and Providers, 1985; 1085-1093. *Invited chapter.*
- Bentkover J, Caper P, Schlesinger M, Suldan J. Medicare's payment of hospitals. In: Blumenthal D, Drumheller P, Schlesinger M, Eds. Renewing the Promise: Medicare and Its Reform. Oxford University Press, 1988:90-115. *(Invited chapter and reviewed by editors).*
- Bentkover JD, Stason WB. Cost-benefit and cost-effectiveness analysis in the evaluation of treatment for cardiovascular disease. Costs of Illness and Benefits of Drug Treatment 1989; 35-44. *Invited chapter.*
- Bentkover, JD, VT Covello, J Mumpower. Benefits Assessment: The State of the Art. Springer, 1986. *Edited this textbook and wrote a chapter funded by an NSF Grant (don't have record of title, number, other info)*
- Multi hospital systems and access to health care. In: Rossiter L, Wilensky G, eds. In: Advances in health services research. JAI Press, 1986. *Invited chapter and reviewed by editors.*

- Bentkover JD, Laroche MR, Russell PM. Managing price throughout the life cycle of a pharmaceutical product: tools, timing and strategies. In: The pharmaceutical pricing compendium. London: Urch Publishing; 2003. p. 39-47. *Invited chapter and reviewed by publisher-chosen reviewers.*
- Blumenthal D, Schlesinger M, Drumheller P. The Harvard Medicare Project. The Future of Medicare. New England Journal of Medicine. 1986; 314:722-728. *(Peer-reviewed and part of Task Force that authored this article and report)*
- Harvard Medicare Project. Medicare: Coming of Age. Cambridge, MA: Division of Health Policy Research and Education, 1986. *Grant-funded. Reviewed by an interdisciplinary faculty committee from HMS, KSG, HBS, and others.*
- Tolpin H, Bentkover J. The economics of sports injuries. In: Vinger P, Hoerner E, eds. Sports Injuries: The Unthwarted Epidemic. Littleton, MA: PSG Publishing, 1981, 1986: 45-56. *Invited chapter and reviewed by editors.*

## REPRESENTATIVE PRESENTATIONS

- Bentkover JD, Stewart EJ, Magar RM, Saffar JM, Greene EG, Parison D. An economic evaluation of hypertension in Ontario. Presented at the International Society of Pharmacoeconomics and Outcomes Research International Meeting, Washington, DC; May 1999. *Industry-sponsored report and presentation.*
- Vohr BR, Oh W, Stewart EJ, Bentkover JD, Gabbard SA, Lemons J, Papile LA, Pye R. An economic evaluation of universal infant hearing screening. Washington, DC. October 1999. *Peer-reviewed.*
- Stewart EJ, Bentkover JD, Frech FH, Doan QD, Bedigian MP. Symptomatology and quality of life assessment in hypertensive patients following a change in treatment regimen. Presented at the Third International Symposium on Angiotensin II Antagonism, London; February 2000. *Peer-reviewed.*
- Annoni G, Corey R, Bachleda M, Bentkover J, Stewart EJ, Kurth H. An economic model of unstable bladder in Italy. Presented at the Fourth Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research; November 2001. *Peer-reviewed.*
- Chapple CR, Hill S, Corey R, Bentkover J, Stewart EJ, Kurth H. An economic model of Unstable Bladder in the United Kingdom. Presented at the International Consultation on Incontinence; July 2001. *Peer-reviewed.*
- Chapple CR, Hill S, Corey R, Bentkover J, Kurth H. Tolterodine: The cost-effective choice for treating unstable bladder in the UK. Presented at the 31st

- Annual Meeting of International Continence Society; September 2001. *Peer-reviewed.*
- Bentkover J, Dhawan R, Kulseng-Hansen S, Corey R, Bachleda M, Kurth H. An economic model of overactive bladder in Norway. Presented at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Seventh Annual International Meeting; May 2002. *Peer-reviewed.*
  - Quintana GS, Martinez Murillo C, Ambriz FR, Benitez AH, Berges A, Collazo JJ, Esparza A, Pompa T, Taboada C, Zavala S, Larochele MR, Bentkover JD. Economic Model of Haemophilia in Mexico. Presented at WFH World Hemophilia Congress; Seville, 2002. *Peer-reviewed.*
  - Bloom MA, Barghout V, Kahler KH, Bentkover JD, Kurth H, Gralnek IM, Spiegel B. (2005, May). The budget impact of tegaserod on a managed care organization formulary. Presented at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual Meeting. *Peer-reviewed.*
  - Kurth H, McKiernan J, Thomas SK, Bentkover JD. (2005, May). Resource utilization among prostate cancer patients with bone pain. Presented at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual Meeting. *Peer-reviewed.*
  - Bentkover JD, Thomas SK, Shaka EC, et al. Diagnosis of bone metastases and utilization of bisphosphonates among advanced prostate cancer patients. Presented at the 2006 American Society of Clinical Oncology (ASCO) – Prostate Symposium; February 2006. *Peer-reviewed.*
  - Bentkover JD, Dorian P, Thibault B, Gardner M, Bloom MA, Barghout V, Kahler KH, Bentkover JD, Kurth H, Gralnek IM, Spiegel B. (2005, May). The budget impact of tegaserod on a managed care organization formulary. Presented at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual Meeting. *Peer-reviewed.*
  - Bentkover JD, Dorian P, Thibault B, Gardner M, Bloom MA, Barghout V, Kahler KH, Bentkover JD, Kurth H, Gralnek IM, Spiegel B. (2005, May). The budget impact of tegaserod on a managed care organization formulary. Presented at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual Meeting. *Peer-reviewed.*
  - Bentkover J, Beresford J, Preblick R, Rogers B, Schachtner A, Swensen A. (2008, May). Unmet medical needs in the treatment of chronic obstructive pulmonary disease. Poster presented at the annual meeting of the American Thoracic Society, Toronto, ON. *Peer-reviewed.*

- Bentkover J, Beresford J, Rogers B, Schachtner A, Swensen A, Dastani H. (2008, May). Patient, caregiver, and physician perceptions of management of chronic obstructive pulmonary disease: Findings from qualitative research. Poster presented at the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research, Toronto, ON. *Peer-reviewed.*

## **MEDIA**

- Talked to press (local radio and TV in RI) about ACA and impact, mental health parity, Race to Inner Space course
- Over the years, talked to press and media about various studies re cost of illness (e.g. cardiovascular disease, diabetic foot ulcers, IBS, incontinence, prostate cancer, erectile dysfunction)

## **ADVISING AND MENTORSHIP**

- Advised, wrote recommendations, helped with job interview practice, assisted with job salary/benefit negotiation, supervised independent studies, read theses and served on committees for the following students, *all* who received success at their top choice school, scholarship, fellowship, job to date (one pending admission to Brown PhD HSPP program):
  - Shivaani Prakash. Member of PhD dissertation committee, helped with job negotiations, hired her as my TA in EMHL and recommended her for part-time employment with Peter Neumann for econ experience
  - Ellen Richardson. Hired her as a case study writer for EMHL, a RA on One Mind grant, and I mentored her during the time she applied to medical school. She entered the Alpert School of Medicine in August of 2014.
  - Chang Liu, Member of PhD dissertation committee, hired him as my TA for TreeAge in PHP 2350, mentored him while applying for jobs
  - Clay Aldern (Rhodes), served as advisor, hired him on One Mind research grant
  - Kirsten Eom, served as an advisor
  - Sheyda Bautista-Saeyan, advised and taught an Independent Study related to One Mind project
  - Nicole Chen, advised
  - Elizabeth McDonnell, a neuro undergrad who I advised and is now in Brown PhD Neuro program
  - Rachel Ratchford, advised

- Ya Yuan Leung, an international undergrad from Hong Kong, advised and mentored and assisted in getting her connected with Access Health International
- David Borcsok, advised and connected with Harvard – MIT VC community
- Katie de Angelis – advised, hired as an TA in EMHL, still a mentor to her as she begins her consulting career in Boston at JSI
- Amrita Chadra – advised, mentored
- Neeraja Krishnaswamy – advised, mentored
- Advised some Tufts students; undergrad econ majors, most who wish to pursue career in consulting (names withheld)
- Advised and wrote recommendations, made calls, introduced students to retained search firms for many of the EMHL students